Dexmedetomidine ameliorates TNBS-induced colitis by inducing immunomodulator effect

Kayhan G., GÜL M., KAYHAN B., Gedik E., ÖZGÜL Ü., Kurtoglu E. L., ...Daha Fazla

JOURNAL OF SURGICAL RESEARCH, cilt.183, sa.2, ss.733-741, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 183 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.jss.2013.03.028
  • Dergi Adı: JOURNAL OF SURGICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.733-741
  • Anahtar Kelimeler: Inflammatory bowel diseases, Dexmedetomidine, Immune response, Cytokines, INTRAABDOMINAL SEPTIC COMPLICATIONS, INFLAMMATORY-BOWEL-DISEASE, REGULATORY T-CELLS, RISK-FACTORS, INTESTINAL INFLAMMATION, GLATIRAMER ACETATE, CROHNS-DISEASE, INTERLEUKIN-10, RESPONSES, SEPSIS
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Background: Since sedatives are often administered to immune-compromised and critically ill patients, our understanding of immunomodulation by sedation will be critical. Dexmedetomidine, a selective alpha(2)-adrenergic receptor agonist, is often used for sedation and analgesia especially in intensive care units. There are conflicting and little data concerning both the effect and the mechanism of dexmedetomidine on immune response. In our study, we aimed to investigate the effect of dexmedetomidine on immune system at two different doses (5 mu g.kg(-1) and 30 mu g.kg(-1)) during inflammatory bowel disease by using an experimental model, which resembles both systemic and local inflammation.